Collaboration and License Agreements - License Agreement with Norgine Pharma UK Limited (Details) - Norgine Pharma UK Limited - Norgine Agreement € in Millions, $ in Millions |
1 Months Ended | 3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|---|
|
Dec. 31, 2025
USD ($)
|
Dec. 31, 2025
EUR (€)
|
Sep. 30, 2026
USD ($)
|
Sep. 30, 2026
USD ($)
|
Dec. 15, 2025
EUR (€)
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||||
| Payment received under license agreement | $ 64.3 | € 55 | |||
| Maximum future clinical, regulatory, and sales milestone to be received | € | € 495 | ||||
| External costs (as a percent) | 25.00% | ||||
| Credit to research and development | $ 3.4 | $ 10.9 | |||
| Credit to prepaid expenses and other current assets | $ 3.3 | $ 3.3 | |||